ravulizumab   Click here for help

GtoPdb Ligand ID: 10168

Synonyms: ALXN-1210 | ALXN1210 | ravulizumab-cwvz | Ultomiris®
Approved drug Immunopharmacology Ligand
ravulizumab is an approved drug (FDA (2018), EMA (2019))
Compound class: Antibody
Comment: Ravulizumab (ALXN1210; Ultomiris) is a humanized monoclonal antibody that binds to human complement component C5. It was developed by Alexion as a next-generation anti-C5 therapy for paroxysmal nocturnal hemoglobinuria (PNH) that was engineered from their already approved PNH agent eculizumab (Soliris), but was designed to have an inherently longer circulating half-life so as to extend dosing intervals to once/month [3].
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
complement C5 Primary target of this compound Hs Antibody Binding 7.7 – 9.3 pKd - 3
⤷ pKd 9.3 (Kd 4.9x10-10 M) [3]
Description: At pH7.4 in a SPR assay.
pKd 7.7 (Kd 2.2x10-8 M) [3]
Description: At pH6.0 in a SPR assay.